Financials data is unavailable for this security.
View more
Year on year Evrofarma SA grew revenues 7.45% from 45.38m to 48.76m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 55.18% net income growth from 1.42m to 2.20m.
| Gross margin | 32.10% |
|---|---|
| Net profit margin | 4.52% |
| Operating margin | 8.29% |
| Return on assets | 4.58% |
|---|---|
| Return on equity | 14.56% |
| Return on investment | 6.25% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Evrofarma SA fell by 780.00k. However, the company earned 3.14m from its operations for a Cash Flow Margin of 6.44%. In addition the company used 2.02m on investing activities and also paid 1.90m in financing cash flows.
| Cash flow per share | 0.3475 |
|---|---|
| Price/Cash flow per share | 4.36 |
| Book value per share | 1.19 |
|---|---|
| Tangible book value per share | 1.18 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.25 |
|---|---|
| Quick ratio | 0.7788 |
| Total debt/total equity | 1.20 |
|---|---|
| Total debt/total capital | 0.5462 |
More ▼
Growth rates in EUR
Year on year, growth in earnings per share excluding extraordinary items increased 55.17%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.83% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 31.05% |
| EPS growth(5 years) | 17.60 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 55.17 |
More ▼
